These data were consistently validated in CD138+ MM cells isolated from the bone marrow of MM patients at distinct stages of disease progression, exhibiting variable basal HLA-E expression (Supplementary Table II), showing that treatment with CX-5461 but not with BMH-21 increased cell surface expression of HLA-E and classical HLA on malignant PCs (Supplementary Fig. 9A, B). The gene discussed is HLA-E; the disease is Miyoshi myopathy.